Arbutus Biopharma (NASDAQ:ABUS) Price Target Increased to $5.00 by Analysts at JMP Securities

Arbutus Biopharma (NASDAQ:ABUS) had its price target hoisted by JMP Securities from $4.00 to $5.00 in a report published on Friday, Benzinga reports. They currently have a market outperform rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently issued reports on the stock. Chardan Capital restated a buy rating and issued a $4.00 target price on shares of Arbutus Biopharma in a report on Wednesday, June 5th. HC Wainwright restated a buy rating and issued a $5.00 target price on shares of Arbutus Biopharma in a report on Thursday, June 6th.

Arbutus Biopharma Stock Down 3.1 %

NASDAQ ABUS opened at $3.62 on Friday. Arbutus Biopharma has a 52 week low of $1.69 and a 52 week high of $3.98. The stock has a market capitalization of $683.17 million, a PE ratio of -7.77 and a beta of 1.96. The firm has a 50 day moving average of $3.39 and a two-hundred day moving average of $2.97.

Arbutus Biopharma (NASDAQ:ABUS) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Arbutus Biopharma had a negative net margin of 766.20% and a negative return on equity of 68.02%. The company had revenue of $1.73 million during the quarter, compared to analyst estimates of $1.54 million. During the same quarter in the previous year, the company posted ($0.10) EPS. On average, equities research analysts expect that Arbutus Biopharma will post -0.39 earnings per share for the current fiscal year.

Institutional Trading of Arbutus Biopharma

Large investors have recently bought and sold shares of the business. nVerses Capital LLC acquired a new stake in Arbutus Biopharma during the 2nd quarter worth $34,000. Walleye Trading LLC acquired a new stake in Arbutus Biopharma during the 1st quarter worth $36,000. China Universal Asset Management Co. Ltd. boosted its stake in Arbutus Biopharma by 351.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 19,400 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 15,104 shares during the period. PFG Investments LLC acquired a new stake in Arbutus Biopharma during the 1st quarter worth $50,000. Finally, Premier Path Wealth Partners LLC boosted its stake in Arbutus Biopharma by 37.4% during the 1st quarter. Premier Path Wealth Partners LLC now owns 30,500 shares of the biopharmaceutical company’s stock worth $79,000 after purchasing an additional 8,300 shares during the period. Institutional investors and hedge funds own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.